BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23098888)

  • 1. Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.
    Chari A; Barley K; Jagannath S; Osman K
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):55-61. PubMed ID: 23098888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
    Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
    Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
    Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
    Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
    Kastritis E; Anagnostopoulos A; Roussou M; Toumanidis S; Pamboukas C; Migkou M; Tassidou A; Xilouri I; Delibasi S; Psimenou E; Mellou S; Terpos E; Nanas J; Dimopoulos MA
    Haematologica; 2007 Oct; 92(10):1351-8. PubMed ID: 18024372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.
    Lee JY; Lim SH; Kim SJ; Lee GY; Lee JE; Choi JO; Kim JS; Kim HJ; Lee SY; Min JH; Jeon ES; Kim K
    Amyloid; 2014 Dec; 21(4):261-6. PubMed ID: 25248716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.
    Mikhael JR; Schuster SR; Jimenez-Zepeda VH; Bello N; Spong J; Reeder CB; Stewart AK; Bergsagel PL; Fonseca R
    Blood; 2012 May; 119(19):4391-4. PubMed ID: 22331188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
    Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J;
    Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
    Adam Z; Pour L; Krejcí M; Zahradová L; Krivanová A; Mardová J; Kovárová L; Stepánková S; Moulis M; Kren L; Veselý K; Svobodová I; Germáková Z; Nedbálková M; Mayer J; Hájek R
    Vnitr Lek; 2010 Mar; 56(3):190-209. PubMed ID: 20394205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
    Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
    Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
    Kumar SK; Hayman SR; Buadi FK; Roy V; Lacy MQ; Gertz MA; Allred J; Laumann KM; Bergsagel LP; Dingli D; Mikhael JR; Reeder CB; Stewart AK; Zeldenrust SR; Greipp PR; Lust JA; Fonseca R; Russell SJ; Rajkumar SV; Dispenzieri A
    Blood; 2012 May; 119(21):4860-7. PubMed ID: 22504925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
    Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
    Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
    Ludwig H; Viterbo L; Greil R; Masszi T; Spicka I; Shpilberg O; Hajek R; Dmoszynska A; Paiva B; Vidriales MB; Esteves G; Stoppa AM; Robinson D; Ricci D; Cakana A; Enny C; Feng H; van de Velde H; Harousseau JL
    J Clin Oncol; 2013 Jan; 31(2):247-55. PubMed ID: 23091109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
    Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M
    J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
    Chang WJ; Kang ES; Lee ST; Kim SH; Kim DW; Kim SJ; Kim K
    Acta Haematol; 2014; 132(2):226-32. PubMed ID: 24732093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
    Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
    Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
    Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
    Ahn JS; Yang DH; Jung SH; Park HC; Moon JH; Sohn SK; Bae SY; Kim YK; Kim HJ; Lee JJ;
    Ann Hematol; 2012 Jul; 91(7):1023-30. PubMed ID: 22314843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.